Drug Trial Radar · NCT07569926
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
142
Planned (sponsor's estimate)
Start
Aug 31, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- Blue Earth DiagnosticsIndustry
- Sponsor type
- Industry
- First posted
- May 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence
Conditions
- Prostate Cancer
Interventions
fluciclovine (18F)Drug
fluciclovine (18F) injection, 370 MBq (10 mCi) ± 20%, delivered as an intravenous bolus.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with any recorded Change In Management following a fluciclovine (18F) PET/CT scan.Time frame: fluciclovine (18F) on Day 1, At least 24 hours after the piflufolastat (18F) scan, but within 30 calendar days
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of California San Diego Health
San Diego, California · Not yet recruiting
Emory University
Atlanta, Georgia · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Washington University
St Louis, Missouri · Not yet recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
Urology Austin
Austin, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.